KIORA PHARMACEUTICALS, INC. Impairment of Intangible Assets (Excluding Goodwill)
KIORA PHARMACEUTICALS, INC. (KPRX) reported Impairment of Intangible Assets (Excluding Goodwill) of $1.77 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2022-04-15
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2021 was $1.77M.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2020 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|
| 2021-12-31 | $1.77M 10-K · filed 2022-04-15 |
| 2020-12-31 | $0.00 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |